Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Fluorouracil + Methylnaltrexone Bromide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 11||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Methylnaltrexone Bromide||Relistor||MNTX||VEGFR Inhibitor (Pan) 32||Relistor (methylnaltrexone bromide) is a mu-type opioid receptor inhibitor and is approved for constipation, but it has also been shown to inhibit VEGFRs and angiogenesis (PMID: 16820176).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Fluorouracil + Methylnaltrexone Bromide||Preclinical||Actionable||In a preclinical study, Relistor (Methylnaltrexone) enhanced the efficacy of Adrucil (fluorouracil) in a variety of human cancer cell lines (PMID: 19661297).||19661297|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|